gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VCYTHealthcareMedical Labs

Veracyte, Inc. (VCYT)

$52.52+4.43%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$51.85▲ 42.26% in range
Nov 3, 2025Low $30.01 · High $60.49Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Veracyte closed at $52.52 on Nov 4, up 4.43%, 13.2% below its 52-week closing high. Volume of 1.9M shares was 1.68× its 20-day average (above normal).

Split-adjusted performance: +17.6% over one month, +27.5% over six months, +44.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $150.32M, up 15.5% from a year earlier, with a net margin of 17.0%.

Short interest was 9.8M shares at the Oct 15 settlement, down 3.5% from the prior report (12.3% of float, 8.5 days to cover).

Market cap$4.22B80.4M shares
Revenue · quarter$150.3M+15.5% YoY
Diluted EPS$0.31—
P/E · TTM36.9×P/S 7.5×
Net margin17.0%Gross 72.2%
Dividend yieldNone
52-week range30.01 – 60.49−13.2% from high
Volume1.9M1.68× 20-day avg
Volatility · 60d54.6%Annualised
Short % of float12.3%8.5 days to cover
Net cash$485.2MCash $485.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.4%1M +17.6%3M +13.8%6M +27.5%YTD +24.8%1Y +44.1%3Y +159.7%5Y +15.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum32
Revenue growth28
Net margin95
Value (low P/E)—
Size61

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short9.8M−3.5% vs prior
Days to cover8.5Settled Oct 15
% of float12.3%
Short vol. 10d67.9%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VCYTVeracyte$52.52+4.43%+27.5%+15.5%17.0%36.9$4.22B
CDNACareDx$85.86−2.95%+309.8%+39.3%13.8%35.1$4.51BCompare
CELCCelcuity$69.24−0.69%−50.3%———$3.39BCompare
BLLNBillionToOne$113.89+3.11%+39.9%—7.4%—$5.37BCompare
RDNTRadNet$80.26+9.67%+36.9%+25.0%1.2%—$6.32BCompare
GRALGRAIL$143.66+3.03%+128.9%+25.7%−246.7%—$6.42BCompare
FTREFortrea Holdings$20.83−0.57%+33.2%−1.4%0.1%—$2.01BCompare
CAICaris Life Sciences$33.22+1.13%+73.7%+45.4%−0.2%89.3$9.39BCompare
PSNLPersonalis$15.79+0.25%+160.1%+30.0%−141.7%—$1.69BCompare

News about Veracyte

All news →
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerGlobeNewswire Inc. · Oct 23, 2026▲ PositiveWill Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 21, 2026▲ PositiveVeracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026GlobeNewswire Inc. · Sep 25, 2026▲ Positive

Quick answers

What does Veracyte do?
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
What is VCYT's market cap?
$4.22B, based on the Nov 4 close of $52.52.
What is VCYT's P/E ratio?
36.9× trailing-twelve-month earnings of $114.48M.
Does Veracyte pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VCYT is sold short?
9.8M shares, 12.3% of float, as of Oct 15, 2026.
What sector is VCYT in?
Healthcare, in the Medical Labs industry.

About Veracyte

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

HQ: South San Francisco, CA755 employeesListed Oct 30, 2013veracyte.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology